Data from NantHealth’s GPS Cancer platform reveals increased opportunities for HER2 directed therapy in colorectal cancer patients

NantHealth Presented These Findings at the ASCO 2020 Gastrointestinal Cancers Symposium

SAN FRANCISCO--(BUSINESS WIRE)-- NantHealth, Inc. (NASDAQ: NH), a next-generation, evidence-based, personalized healthcare company, today announced Results of a fifty-gene breast cancer RNA subtype classifier applied to 167 colorectal cancer (CRC) patients during a poster session at the 2020 Gastrointestinal Cancer Symposium sponsored by the American Society of Clinical Oncology (ASCO).

The Symposium, held at the Moscone West Building in San Francisco, CA from January 23-25, provides evidence-based teaching methods and cutting-edge learning science to a diverse audience of leaders in oncology education, doctors and care teams.

NantHealth’s presentation utilized data on whole exome (WES) DNA tumor and paired germline and matched deep whole transcriptomic sequencing (RNA-Seq) to identify a higher percentage of CRC patients with HER2 signaling than conventional methods of immunohistochemistry (IHC) or fluorescence in-situ hybridization (FISH). ERBB2 (HER2) gene expression was evaluated using NantOmics Nant50 gene classifier, which separates patients into subgroups that have been well established in breast cancer. The application of this tool to colorectal cancer proved surprising with greater than expected HER2 positive patients with a normally expected distribution of CMS classification (consensus molecular subtype in CRC). This finding suggests a possible utility for this tool in a new clinical setting. In addition, the HER2 enriched group did not show differentially expressed mutations in other targetable genes such as PIK3CA and BRAF, highlighting the potential importance of HER2 targeting in this population.

“Our analysis shows that conventional testing methods may miss potentially actionable HER2 signaling in CRC patients,” said Sandeep “Bobby” Reddy, MD, Chief Medical Officer, NantHealth. “The significant difference suggests that up to 40% more patients may be eligible for HER2 directed therapies, which has implications for drug development and clinical trials.”

Title: “Results of a fifty-gene breast cancer RNA subtype classifier applied to 167 colorectal cancer (CRC) patients”

Authors: Sandeep K. Reddy, M.D., Tara Elisabeth Seery, M.D., Christopher W. Szeto, Ph.D.

Poster Session and Number: Poster session C (Board #A14)

Location: Moscone West Building

Date and Time: January 25, 2020, 6:30-7:55 AM PT and 12:15-1:45 PM PT

About NantHealth:

NantHealth, a member of the NantWorks ecosystem of companies, provides leading solutions across the continuum of care for physicians, payors, patients and biopharmaceutical organizations. NantHealth enables the use of cutting-edge data and technology toward the goals of empowering clinical decision support and improving patient outcomes. NantHealth’s comprehensive product portfolio combines the latest technology in payor/provider platforms that exchange information in near-real time (NaviNet and Eviti), connected care solutions that deliver medical device interoperability (DCX device connectivity platform and VCX patient vitals software) and molecular profiling services that combine comprehensive DNA & RNA tumor-normal profiling with pharmacogenomics analysis (GPS Cancer^®). For more information, please visit www.nanthealth.com or follow us on Twitter, Facebook and LinkedIn.

About NantOmics:

NantOmics, a member of the NantWorks ecosystem of companies, invented and developed the technologies that drive NantHealth’s GPS Cancer^® platform. GPS Cancer^® provides actionable intelligence and molecularly driven decision support for cancer patients and their providers at the point of care. NantOmics is the first molecular analysis company to pioneer an integrated approach to unearthing molecular variances and profiles that initiate and drive cancer, by analyzing both normal and tumor cells from the same patient and following identified variances from DNA to RNA to protein to drug. Having pioneered tumor-normal DNA sequencing and introduced whole RNA transcriptomic analysis to better inform clinical treatment decisions, NantOmics has provided molecular insights for thousands of cancer patients.

NantOmics has a highly scalable cloud-based infrastructure capable of storing and processing thousands of genomes a day, computing genomic variances in near real-time and correlating proteomic pathway analysis with quantitative gene expression and pharmacogenomic signatures, which guides the use of immunotherapies, chemotherapies and targeted therapies. Clinical studies for neoepitope vaccines using NantOmics’ proprietary technologies and novel artificial intelligence platforms are currently underway. For more information please visit www.nantomics.com.

Forward-Looking Statements: NantHealth

This news release contains certain statements of a forward-looking nature relating to future events or future business performance. Forward-looking statements can be identified by the words “expects,” “anticipates,” “believes,” “intends,” “estimates,” “plans,” “will,” “outlook” and similar expressions. Forward-looking statements are based on management’s current plans, estimates, assumptions and projections, and speak only as of the date they are made. Risks and uncertainties include, but are not limited to: our ability to successfully integrate a complex learning system to address a wide range of healthcare issues; our ability to successfully amass the requisite data to achieve maximum network effects; appropriately allocating financial and human resources across a broad array of product and service offerings; raising additional capital as necessary to fund our operations; achieving significant commercial market acceptance for our sequencing and molecular analysis solutions; establish relationships with, key thought leaders or payers’ key decision makers in order to establish GPS Cancer as a standard of care for patients with cancer; our ability to grow the market for our Systems Infrastructure, and applications; successfully enhancing our Systems Infrastructure and applications to achieve market acceptance and keep pace with technological developments; customer concentration; competition; security breaches; bandwidth limitations; our ability to continue our relationship with NantOmics; our ability to obtain regulatory approvals; dependence upon senior management; the need to comply with and meet applicable laws and regulations; unexpected adverse events; clinical adoption and market acceptance of GPS Cancer; and anticipated cost savings. We undertake no obligation to update any forward-looking statement in light of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements as a result of the impact of a number of factors, many of which are discussed in more detail in our reports filed with the Securities and Exchange Commission.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200125005009/en/